Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (888) 282-7099 Click to print page  Print

Browse Trials


In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.


Currently viewing trials
(Last updated: June 14, 2021)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

1

NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX

VISITS: May require hospital stay

PHASE: I-II

NCT ID: NCT04727151

TAC T Cell Immunotherapy for Metastatic HER2 Positive Breast Cancer

A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors Scientific Title

Purpose
To study the safety, anti-cancer activity, and dose of T cell immunotherapy designed to target HER2.
Who is this for?
People with metastatic (stage IV) HER2 positive breast cancer who have received at least two anti-HER2 therapies.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fludarabine and cyclophosphamide, by IV</li> </ul> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">followed by TAC01-HER2, by IV, 1 time</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">A hospital stay may be required.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TAC01-HER2 is an experimental TAC T cell immunotherapy.</li> <li class="seamTextUnorderedListItem">TAC T cell therapy is personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">The TAC T cell therapy being used in this study trains the immune system to attack HER2 positive cancer cells.</li> <li class="seamTextUnorderedListItem">Before you are given the immunotherapy, you will be given the chemotherapies fludarabine and cyclophosphamide. These chemotherapies are given to prepare your immune system to receive the TAC T cell immunotherapy. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of HER2 positive cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04727151' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://triumvira.com/technology-science/tac-car-t-tcr-development-pipeline/' target='_blank'>Triumvira Drug Information Page: TAC01-HER2</a> </li><li class='seamTextUnorderedListItem'><a href='https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&version=21.03e&code=C178298&ns=ncit' target='_blank'>NCI Thesaurus: TAC01-HER2</a> </li></ul>
See more